1. Home
  2. UDMY vs LBRX Comparison

UDMY vs LBRX Comparison

Compare UDMY & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Udemy Inc.

UDMY

Udemy Inc.

HOLD

Current Price

$4.86

Market Cap

716.5M

Sector

Real Estate

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

N/A

Current Price

$30.80

Market Cap

602.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UDMY
LBRX
Founded
2009
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
716.5M
602.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
UDMY
LBRX
Price
$4.86
$30.80
Analyst Decision
Buy
Strong Buy
Analyst Count
8
5
Target Price
$9.29
$46.60
AVG Volume (30 Days)
1.5M
299.4K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
105.36
N/A
EPS
0.03
N/A
Revenue
$789,844,000.00
N/A
Revenue This Year
$4.12
N/A
Revenue Next Year
$4.54
N/A
P/E Ratio
$171.63
N/A
Revenue Growth
0.42
N/A
52 Week Low
$4.02
$13.40
52 Week High
$8.09
$33.47

Technical Indicators

Market Signals
Indicator
UDMY
LBRX
Relative Strength Index (RSI) 51.59 62.29
Support Level $4.30 $21.90
Resistance Level $5.20 N/A
Average True Range (ATR) 0.32 2.05
MACD 0.01 0.18
Stochastic Oscillator 65.02 71.77

Price Performance

Historical Comparison
UDMY
LBRX

About UDMY Udemy Inc.

Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Enterprise segment and Consumer segment, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America, and also has its presence in Europe, Middle East, Africa; Asia Pacific; and Latin America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Share on Social Networks: